Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer

Florenzano, Pablo; Guarda, Francisco J; Jaimovich, Rodrigo; Droppelmann, Nicolás; González, Hernán; Domínguez, José Miguel

doi:10.1155/2016/2586512

Cited by 15 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, RAI use is associated with short-and long-term adverse effects, which can significantly impair patients' quality of life. For this reason, the indication of RAI must be adjusted to the patient's individual risk of recurrence and mortality (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation

Zavala¹,

Barra²,

Olmos³

et al. 2019

Archives of Endocrinology and Metabolism

Self Cite

View full text Add to dashboard Cite

Objective: Our objective was to evaluate the trend of antithyroglobulin antibodies (TgAb) during follow-up of patients with differentiated thyroid cancer (DTC) treated without RAI, as well as their role in the risk of recurrence. Subjects and methods: This was a prospective, descriptive study. A total of 152 consecutive patients with DTC treated in a single institution undergoing total thyroidectomy without RAI and followed for a median of 2.3 years (0.5-10.3) were divided in two groups: TgAb(-) (n = 111) and TgAb(+) (n = 41). Patients were classified according to AJCC 7 th and 8 th editions, as well as to their risk of recurrence and response to treatment categories. Results: Both groups, TgAb(-) and TgAb(+), were similar regarding patient and tumor characteristics. At the end of follow-up, 90 (59.2%), 57 (37.5%), 3 (2%) and 2 (1.3%) patients achieved excellent, indeterminate, biochemically incomplete and structurally incomplete response, respectively. The risk of structural recurrence was similar in both groups (TgAb[-] 0.9% vs. TgAb[+] 2.4%, p = 0.46). In the TgAb(+) group, TgAb became negative in 10 (24.4%), decreased ≥ 50% without negativization in 25 (60.9%), decreased < 50% in 4 (9.8%) and remained stable or increased in 2 (4.9%) cases. The only incomplete structural response had increasing TgAb during follow-up. Conclusions: In properly selected patients with DTC, TgAb concentration immediately after total thyroidectomy should not mandate RAI ablation, and their trend during follow-up may impact the risk of recurrence. Arch Endocrinol Metab. 2019;63(3):293-9

show abstract

Section: Introductionmentioning

confidence: 99%

In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation

Zavala¹,

Barra²,

Olmos³

et al. 2019

Archives of Endocrinology and Metabolism

Self Cite

View full text Add to dashboard Cite

show abstract

“…La importancia de este punto radica en que, además de no mejorar el pronóstico de estos pacientes, estas terapias tienen efectos adversos. En el caso del RAI, incluso, la administración de dosis bajas se ha asociado a sialoadenitis, obstrucción del conducto lagrimal, alteraciones del sentido del gusto y manifestaciones clínicas del hipotiroidismo o costo económico del rhTSH requerido para su administración, entre otros 15 . En relación a la supresión de TSH, el hipertiroidismo subclínico es un reconocido factor de riesgo para arritmias, osteoporosis y fracturas, particularmente en mujeres postmenopáusicas 16 .…”

Section: Discussionunclassified

Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSAL

Domínguez¹,

Martínez²,

Massardo

et al. 2018

Rev. méd. Chile

Self Cite

View full text Add to dashboard Cite

show abstract

“…Total thyroidectomy followed by RAI has been associated with benefits in high-risk patients, as well as in the decrease in TCA recurrence. Current guidelines recommend an individualized approach for RAI indication [133] because its benefit in low-risk patients was not supported by evidence [134][135][136]. Despite the potential adverse effects of RAI, its application increases in patients with DTCA [137,138].…”

Section: Thyroid Malignanciesmentioning

confidence: 99%

Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism

Tribulová

Kurahara

Hlivák

et al. 2020

IJMS

View full text Add to dashboard Cite

A perennial task is to prevent the occurrence and/or recurrence of most frequent or life-threatening cardiac arrhythmias such as atrial fibrillation (AF) and ventricular fibrillation (VF). VF may be lethal in cases without an implantable cardioverter defibrillator or with failure of this device. Incidences of AF, even the asymptomatic ones, jeopardize the patient’s life due to its complication, notably the high risk of embolic stroke. Therefore, there has been a growing interest in subclinical AF screening and searching for novel electrophysiological and molecular markers. Considering the worldwide increase in cases of thyroid dysfunction and diseases, including thyroid carcinoma, we aimed to explore the implication of thyroid hormones in pro-arrhythmic signaling in the pathophysiological setting. The present review provides updated information about the impact of altered thyroid status on both the occurrence and recurrence of cardiac arrhythmias, predominantly AF. Moreover, it emphasizes the importance of both thyroid status monitoring and AF screening in the general population, as well as in patients with thyroid dysfunction and malignancies. Real-world data on early AF identification in relation to thyroid function are scarce. Even though symptomatic AF is rare in patients with thyroid malignancies, who are under thyroid suppressive therapy, clinicians should be aware of potential interaction with asymptomatic AF. It may prevent adverse consequences and improve the quality of life. This issue may be challenging for an updated registry of AF in clinical practice. Thyroid hormones should be considered a biomarker for cardiac arrhythmias screening and their tailored management because of their multifaceted cellular actions.

show abstract

Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer

Cited by 15 publications

References 25 publications

In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation

In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation

Riesgo de recurrencia en cáncer diferenciado de tiroides: escala MINSAL

Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism

Contact Info

Product

Resources

About